Polymyxin B is an antibiotic primarily used for resistant gram-negative infections. Polymyxins bind to the cell membrane and alter its structure making it more permeable. The resulting water uptake leads to cell death. They are cationic, basic proteins that act like detergents (surfactants). It is ordinarily habituated in the topical first-aid preparation Neosporin.
Polymyxin B (Sulphate) is a cationic, more common peptide comprises greasy caustic D-6-methyloctan-1-oic blistering and amino acids L-threonine and L-diaminobutyric acid. Polymyxin B (Sulphate) is used in the treatment of respective systemic, urinary parcel of land, otic, ophthalmic and cutaneous infections due to susceptible gram -ve bacteria. Polymyxin B (Sulphate) is administered orally, parentrally and topically, but nowadays, rarely used parentrally due to its potential for causing nephrotoxicity and/or neurotoxicity.
Polymyxin B (Sulphate) is more commonly administered as either a topical or otic broker inward compounding with neomycin or bacitracin. Polymyxin B (Sulphate) is also available in ophthalmic solutions in combination with either trimethoprim B vitamin or inward combination with bacitracin and neomycin. Polymyxin B is also used in combination with neomycin as a urinary tract irrigant. Polymyxin B was originally approved by the FDA in 1951.
No comments:
Post a Comment